NeuVax is a peptide-based immunotherapy that recruits the immune system to fight cancer and activates "Killer T-cells" to target tumors. NeuVax specifically targets cancer while leaving normal, healthy tissues unharmed. The key to NeuVax is a small peptide called E75 that is derived from HER2/neu, a protein expressed by tumors.

T-cells from NeuVax-treated patient attacking cancer.

Unlike existing monoclonal antibody therapy which requires frequent, ongoing, intravenous (I.V.) infusion, NeuVax can produce continuing activation of the immune system and therapeutic levels of Killer T-cells with a once monthly intradermal (under the skin) dosing schedule that is less expensive and more convenient for both the patient and physician.

NeuVax is currently undergoing clinical testing for the adjuvant (after-surgery) treatment of early-stage HER2/neu-expressing breast and prostate cancer. NeuVax may also be developed to treat other types of solid tumors.

Contact us to request more information about NeuVax.